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Apolipoprotein L2 contains a BH3-like domain but it
does not behave as a BH3-only protein
J Galindo-Moreno1, R Iurlaro1, N El Mjiyad1, J Dı́ez-Pérez2,3, T Gabaldón2,3,4 and C Muñoz-Pinedo*,1
Apolipoproteins of the L family are lipid-binding proteins whose function is largely unknown. Apolipoprotein L1
and apolipoprotein L6 have been recently described as novel pro-death BH3-only proteins that are also capable of regulating
autophagy. In an in-silico screening to discover novel putative BH3-only proteins, we identified yet another member of
the apolipoprotein L family, apolipoprotein L2 (ApoL2), as a BH3 motif-containing protein. ApoL2 has been suggested to behave
as a BH3-only protein and mediate cell death induced by interferon-gamma or viral infection. As previously described, we
observed that ApoL2 protein was induced by interferon-gamma. However, knocking down its expression in HeLa cells did not
regulate cell death induced by interferon-gamma. Overexpression of ApoL2 did not induce cell death on its own. ApoL2 did
not sensitize or protect cells from overexpression of the BH3-only proteins Bmf or Noxa. Furthermore, siRNA against ApoL2 did
not alter sensitivity to a variety of death stimuli. We could, however, detect a weak interaction between ApoL2 and Bcl-2 by
immunoprecipitation of the former, suggesting a role of ApoL2 in a Bcl-2-regulated process like autophagy. However, in contrast
to what has been described about its homologs ApoL1 and ApoL6, ApoL2 did not regulate autophagy. Thus, the role, if any, of
ApoL2 in cell death remains to be clarified.
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Bcl-2 family proteins regulate mitochondrial permeability to
control apoptosis. These proteins induce or inhibit cell death,
and they are associated with a growing number of patho-
logies, including cancer and immune diseases.1,2 For this
reason, the search of new members of this family is of crucial
importance. A subfamily of Bcl-2 homologs termed ‘BH3-only
proteins’ comprises a growing number of proteins that only
share a small motif of 15–21 amino acid residues.3,4 This
region, known as the ‘BH3-domain’, is essential for the
apoptotic function of Bcl-2 family proteins. The homology in
this region is relatively loose, and only a few residues are
conserved among the members of the family. For this reason,
BH3-only proteins have been identified by functional means
rather than by sequence homology.
To identify novel BH3-only proteins we used a bio-
informatics approach known as profile-based homology
search. In brief, we constructed a so-called Hidden Markov
Model (HMM) of the BH3-domain from the alignment of a set
of proteins known to bear this domain. This HMM describes
the probabilities of finding a given amino acid at a given
position of the domain. This probabilistic model is then used to
search in a sequence database for proteins that are likely to
encode the same domain.
One of the proteins identified by this method was the
apolipoprotein L2 (ApoL2). Two other members of this family,
ApoL1 and ApoL6 have been described to behave as
proapoptotic BH3-only proteins.5–7 Although the functions of
these proteins are still unclear, proteins of this family have
been shown to bind lipids and they have been suggested to
work as pore-forming proteins in intracellular membranes,
based on the ability of ApoL1 to form pores in the lysosomal
membrane of trypanosomes.8,9 ApoL2 is highly homologous
to ApoL1, and its BH3-like domain is very similar to those of
ApoL1 and ApoL6. For these reasons, we explored the
function of ApoL2 as a putative new BH3-only protein.
Results
Identification of novel BH3-containing proteins by using
a profile-based homology search. Profile-based searches
with profiles of BH3 domains as defined in ProSite10 and
PFAM,11 as well as regular expression searches with motifs
defined in the literature failed to provide satisfactory results in
terms of specificity and sensitivity of detecting known human
BH3 proteins (Table 1). Therefore, to efficiently identify novel
putative BH3-only proteins, we collected the sequences of all
human and mouse BH3 motifs annotated in Uniprot as well
as those described in the literature, and aligned them to
subsequently build an HMM for the BH3-domain (see
Materials and Methods) (Figure 1a). This HMM provided
better results in finding known BH3 than existing profiles at
Pfam (Table 1), and was therefore used to search for
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putative novel BH3-containing proteins in the human
proteome and genome.
Our screening identified BFK, a known Bcl-2 homolog
originally left out from the list of proteins used to build the
model,12 and PXT1, a protein that has been recently
described as a BH3-only protein that kills HeLa cells in a
manner dependent of its BH3 motif13 (Table 2). Another
protein identified by this screening was the apolipoprotein L2
protein (Figure 1b, Table 2). Two apolipoproteins of the
L family, ApoL1 and ApoL6, have been previously identified as
BH3-only proteins.5–7 ApoL2, due to its homology with ApoL1
and ApoL6 has indeed been proposed to be a BH3-only
protein.14 ApoL2 mRNA is ubiquitously expressed, according
to the database IST Online (Supplementary Figure 1). We
checked that this protein is expressed in a variety of cell lines
of different origins (Figure 2a), and highly expressed in HeLa
cervical cancer cell line, as predicted due to its high
expression in cervical cancer.15 ApoL2 is localized in HeLa
cells outside the nucleus in a punctate state (Figure 2b) and it
is not secreted (Figure 2c). Although it had been predicted to
interact with membranes,16 we observed that it did not
colocalize with mitochondrial, endoplasmic reticulum or
lysosomal markers (Figure 2b).
ApoL2 is transcriptionally induced by interferon-gamma in
a number of non-transformed tissues.14 In human bronchial
epithelial cells its downregulation sensitized cells to cell
death induced by IFN-g, indicating that ApoL2 is an
antiapoptotic protein in this context.14 We observed that in
HeLa cells IFN-g induces ApoL2 (Figure 2d). However, when
we downregulated ApoL2 using two different silencing
sequences, we could not observe sensitization to cell death
(Figure 2e).
ApoL2 is not a proapoptotic BH3-only protein. To
check whether ApoL2 behaves as a proapoptotic Bcl-2
family member, we overexpressed ApoL2 in HeLa cells.
Overexpression was confirmed by immunofluorescence
(Supplementary Figure 2) and western blot (Supplementary
Figure 3). We used Noxa and Bmf as proapoptotic BH3-only
proteins, and verified that these proteins killed HeLa cells
(Figure 3a). However, ApoL2 did not. We observed a trend of
lower background death in cells overexpressing ApoL2,
suggesting that ApoL2 is an antiapoptotic Bcl-2 family
protein. To test this we overexpressed ApoL2 in combination
with Noxa or Bmf. Our results indicate that ApoL2 confers a
minor protection from Noxa (Figure 3a). However, this did not
Table 1 Summary of the results obtained from direct motif searches in the
human proteome when using different strategies






1. Youle et al.4 5908 13 68.4%
2. Liu et al.7 152 16 84.2%
3. Prosite 28 9 47.36%
4. Novel HMM 26 19 100%
First column indicates the search strategy: using a direct search with (1) The
consensus BH3 motif (LXXXGD) as defined in Youle et al.4 (2) The extended
motif (LXXX[GAS][DE]) used by Liu et al.7 in their identification of Apol6; (3) The
motif defined by Prosite10 as of December 2008; and (4) an HMM-based search
with the profile derived in this work. The following columns indicate,
respectively, the number of total hits in the human proteome (Ensembl42
version), the number of known Bcl-2 family members identified of a total of 19
human members described in Youle et al.4 and Uniprot (2008), and, finally the
sensitivity of the search as computed by dividing the total number of correctly
identified Bcl-2 family members (TP) by the total number of known Bcl-2 family
members (TPþFN¼ 19). TP and FN stand for True Positives and False
Negatives, respectively
Figure 1 ApoL2 contains a BH3-like motif. (a) Logo representation of the protein profile used in the search for new BH3-domain proteins. The logo indicates the probability
of finding a given amino acid at each of the 15 positions of the BH3-domain. Amino acids are represented by the one-letter code, and their height is proportional to the
probability of appearing at a given position in the BH3-domain. (b) Alignment of ApoL2 BH3 motif with other BH3 motifs
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reach statistical significance (n¼ 3). Bcl-2 was employed as
a control (expression checked in Supplementary Figure 3)
and it protected from Noxa and Bmf.
Next we analyzed whether ApoL2 would regulate cell death
induced by a variety of stimuli, either by behaving as an
antiapoptotic protein as described14 or as a proapoptotic
Table 2 Summary of the putative BH3-only proteins predicted using HMM
Name UniProt
ID
NM ID Amino acid
number
Ensembl ID
Apolipoprotein L2 (ApoL2) Q9BQE5 NM_030882.2 and NM_145637.1 337 ENSG00000128335
Arf-GAP with coiled-coil, ANK repeat and PH
domain-containing protein 3 (ACAP3)
Q96P50 NM_030649.2 834 ENSG00000131584
GDP-fucose protein O-fucosyltransferase 2 (POFUT2) Q9Y2G5 NM_015227.4 429 ENSG00000186866
Phenylalanine-4-hydroxylase(PHA) P00439 NM_000277.1 452 ENSG00000171759
Peroxisomal testis-specific protein 1 (PXT1) J3KR74 NM_152990.3 134 ENSG00000179165
Uncharacterized protein C19orf55 (C19orf55) Q2NL68 NM_001039887 480 (putative) ENSG00000167595
The table shows the different identification codes of the gene from the major databases. Uniprot ID (http://www.uniprot.org/), NM ID (http://www.ncbi.nlm.nih.gov/)
and Ensembl ID (http://www.ensembl.org/) as well as the number of amino acids of the protein
Figure 2 Cytosolic ApoL2 is widely expressed in different cell lines and induced by interferon-gamma. (a) ApoL2 expression was tested in different cell lines by western
blot: A549 (A5), FaDu, A-431 (A4), HCT116 (H), 435P (43), HLE, HepG2 (G), HEK293 (293) and HeLa cells. (b) Intracellular localization of ApoL2. HeLa cells were stained
with MitoTracker red (MTR) as mitochondrial marker. Antibodies against Grp94 and Calnexin were used as endoplasmic reticulum markers. Lysosomal localization was
studied using Lamp-2 antibody. Scale bars of 20 mm are shown. (c) ApoL2 is not secreted. Western blot of trichloroacetic acid (TCA)-concentrated medium or cell lysate is
shown. DMEM and DMEM complemented with FBS were used as controls. CM FBS : conditioned medium of HeLa cells grown for 48 h in DMEM without FBS. Lysate: cell
lysate of HeLa cells grown in FBS containing medium for 48 h. CM: conditioned medium of HeLa cells grown in FBS containing medium for indicated times. Antibodies against
ApoL2, tubulin, actin and the secreted protein metalloproteinase-2 (MMP-2) were used for immunoblotting. (d) HeLa cells were transfected with siRNA ApoL2-II, treated with
interferon-gamma (IFN) at 100 or 500 nM for 24 h and collected for western blot. NT means non treated. (e) HeLa cells were transfected with siRNA control 1 or siRNA against
ApoL2 and treated with IFN-g 100 nM for 72 h. Cell death was measured by PI incorporation at the flow cytometer. Figure shows average and S.E.M. of three independent
experiments
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BH3-only protein like ApoL1 and ApoL6. We knocked down
ApoL2 using different siRNA sequences and treated HeLa
cells with the endoplasmic reticulum stressor thapsigargin, the
DNA damaging agent actinomycin D, the lysosomal inhibitor
chloroquine, or starvation of serum, glucose or serum/amino
acid/vitamins (culture in EBSS buffer) (Figures 3b–d). We only
observed a minor difference in cell death induced by
actinomycin D that was significant when cells were depleted
of ApoL2 using one siRNA oligo but not the second one.
ApoL2 has been shown to be induced by TNF.6 We did not
observe induction of ApoL2 upon TNF treatment in HeLa or
293T cells (Supplementary Figure 4). In addition, we treated
HeLa cells with TNF in the presence of cycloheximide to
induce cell death, and we did not observe any difference when
ApoL2 was silenced (Figure 3c).
ApoL2 interacts weakly with Bcl-2 but it does not
regulate autophagy. We could not detect a role of ApoL2
in cell death. However, not all BH3-only proteins described to
date regulate cell death. Some proteins like Beclin-1 regulate
autophagy through its interaction with Bcl-2 family proteins.
ApoL6, which induces cell death and inhibits autophagy, has
Figure 3 ApoL2 does not regulate cell death of HeLa cells. (a) Plasmids encoding two different BH3-only proteins (0.5mg of Bmf and 0.8mg of Noxa plasmids) were
cotransfected with ApoL2 or Bcl-2 and analyzed by microscopy. GFP (0.3mg) was used as transfection marker. ApoL2 and Bcl-2 plasmids were used at amounts shown.
Empty plasmid was used to normalize the amount of transfected DNA. Dead green cells were scored by shrunk morphology and counted from images using fluorescence
microscopy. Figure shows average and S.E.M. of three experiments. For statistical analysis, each ApoL2 or Bcl-2 overexpressing condition has been compared with the empty
plasmid condition transfected with the same BH3-only protein. NS, nonsignificant. (b, c, d). HeLa cells were transfected with different control siRNAs or siRNA against ApoL2
and then treated with chloroquine, deprived of glucose (glc ), incubated in starvation buffer (EBSS) or treated with tumor necrosis factor (TNF) or actinomycin D (ActD) for
24 h (b, c), or deprived of serum (FBS ) or treated with thapsigargin (Thaps) for 72 h (d). Cell death was measured by PI incorporation by flow cytometry. Figure shows
average and S.E.M. of three (d) or five experiments (b, c). Asterisks or NS (nonsignificant) denote significance versus Control 2 (b) or Control 1 (c)
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been shown to bind Bcl-xL.17 We thus tested whether
endogenous ApoL2 interacted with other BH3-containing
proteins. We immunoprecipitated ApoL2 and blotted for
multidomain Bcl-2 family proteins. Bcl-2 was reproducibly
immunoprecipitated with ApoL2 (Figure 4a). We were unable
to immunoprecipitate endogenous Bcl-2 under the same
conditions (not shown). For these reasons, to confirm
these interactions in a different manner we overexpressed
HA-tagged Bcl-2.18 Under these conditions, we were
unable to immunoprecipitate ApoL2 with anti-HA antibody
(Figure 4b) or to detect HA upon immunoprecipitation of
ApoL2, neither in HeLa nor in 293T cells (not shown).
We next checked whether the weak interaction between
ApoL2 and Bcl-2 (detected only using endogenous proteins)
would alter the sensitivity of HeLa cells to the Bcl-2 and
Bcl-xL inhibitor ABT-737. Downregulation of ApoL2 did not
alter the amount of cell death induced by ABT-737 (Figure 5a).
One possibility is that ApoL2, by interacting with Bcl-2 or
signaling lipids, would regulate cell proliferation. We tested
this and could not observe any effects on cellular proliferation
by downregulation of ApoL2 (Figure 5b). We next investigated
whether ApoL2 could act like Beclin-1 or ApoL6 regulating
autophagy.17 We downregulated ApoL2 (Figures 6a and b)
and measured basal autophagy (lipidation of LC3 and
degradation of p62 in the presence or absence of protease
inhibitors) and starvation-induced autophagy (same measure-
ments after incubation in starvation buffer EBSS). Our results
indicate that ApoL2 does not alter basal or starvation-induced
autophagic flux as measured by levels of LC3-II (Figures 6a
and c). We did observe a significant reduction of p62 levels
after ApoL2 was downregulated, suggesting that this protein
regulates basal autophagy (Figures 6a and d), but this was not
accompanied by a difference in levels of LC3-II at these
conditions (Figure 6c).
Altogether, our data indicate that ApoL2 is not a classical
BH3-only protein, and its exact function in cell death by
interferon treatment remains to be determined.
Discussion
BH3-only proteins do not share a high degree of homology
between them, and it is possible that the BH3-domain arose
either randomly during evolution or by a process of con-
vergent evolution.19 Moreover, the BH3-domain is not
extremely well conserved even among Bcl-2 family proteins
that share more domains than the BH3.3 Many BH3-only
proteins have not been identified by sequence, but on the
basis of their interaction with Bcl-2 family proteins. Other
members of this family have been found to be proapoptotic
proteins and the putative BH3-motif was identified later. We
have performed here a search based on a newly-generated
protein composition profile that was shown to identify all
known BH3-only proteins plus few additional candidates in the
human genome.
Our screening identified the protein PXT1, which has a
BH3-like domain. This protein has been described to induce
cytochrome c release and apoptosis in HeLa cells in a manner
dependent on its BH3 motif.13 In addition, apolipoprotein L2
(ApoL2) caught our attention due to the recent description of
ApoL2 homologs as BH3-only proteins. ApoL1, the founding
member of the family, was identified as a component of a
class of high density lipoproteins (HDL) in human blood.20 In
subsequent years, a number of homologous proteins have
been described: the apolipoprotein L family comprises six
members in humans and 8–14 members in rodents.16,21
ApoL1 is the only member of the family expected to be
secreted, and when internalized by trypanosomes it gener-
ates pores in their lysosomal membrane.8 ApoL1 and ApoL6
also kill mammalian cells when overexpressed, and it has
been proposed that all members of the family could share this
ability with these two proteins.9 Induction of cell death by
ApoL1 and ApoL6 was prevented when their BH3 motif was
deleted.5,7 Both proteins bind lipids;5,7 interestingly, ApoL1
binds cardiolipin which is a lipid required for permeabilization
of liposomes by Bcl-2 family members.22 ApoL6 binds Bcl-xL
Figure 4 Immunoprecipitation of ApoL2 in HeLa cells. (a) Endogenous ApoL2 was immunoprecipitated (IP) and the presence of the indicated proteins was assayed by
western blot. Blots from a single experiment representative of three independent experiments are shown. (b) HeLa cells were transfected with HA-Bcl-2 or empty vector. Anti-
HA was used for immunoprecipitation and the presence of ApoL2, Bcl-2 and HA was assayed by western blot. Panel shown is representative of three independent
experiments. Left and right panels were cropped from the same films
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and it regulates autophagy.17 So indeed, many similarities
exist between some members of the apolipoprotein L family
and ‘classic’ Bcl-2 family proteins.
ApoL2 has been shown to be antiapoptotic in primary cells
treated with interferon-gamma.14 Recently, ApoL2 has been
identified as a protein that translocates to mitochondria in cells
infected with H3N2 swine influenza virus.23 These two facts,
together with the description of other proteins of the family as
BH3-only proteins has led to propose that ApoL2 has a role in
apoptosis, which we have not been able to confirm. It is
possible that the aspartic residue in position 10 of the motif
(Figure 1) is essential for their proapoptotic function. The
function of other Bcl-2 family members with a glutamic acid in
that position, Bcl-Rambo (Bcl2L13) and Bcl-G (Bcl2L14), is
still not fully defined, but their main function may be unrelated
to cell death.24,25
We have detected a weak interaction between Bcl-2 and
ApoL2. However, this did not alter apoptosis induced by many
stimuli or starvation-induced autophagy. We did observe a
basal regulation of p62, an autophagic protein, which could
suggest that this protein regulates autophagy under certain
conditions due to its interaction with Bcl-2. On the other hand,
Bcl-2 regulates multiple metabolic pathways, Ca2þ stores in
the endoplasmic reticulum, mitochondrial morphology and
DNA repair.26,27 We have not explored here the possibility that
ApoL2 regulates these functions of Bcl-2. Nonetheless, it is
also possible that the ApoL2 has a cell-type or stimulus-
dependent role on cell death that according to our data is not
general or ubiquitous.
Materials and Methods
Building the HMM. Sequences of vertebrate proteins annotated with the
BH3-domain in Uniprot and the literature as of November 2008 (Bcl-2, Bcl-XL,
Bcl-w, Mcl-1, Bcl-Rambo, Bcl-G, Bax, Bak, Bok, Bim, Bid, Bad, Bmf, Noxa, Hrk,
Puma, Bik, Blk, Mule, Spike, Nix, BNIP3, Map-1, Cul7, Beclin-1, p53, ApoL6,
ApoL1 and AVEN) were aligned with MAFFT.28 A 15-residue long region from the
alignment containing the annotated BH3 domains was selected using trimAl 1.3,29
and a HMM model was built for the region using HMMER v1.8.5.30 HMMER was
used to search in the entire human proteome, as retrieved from Ensembl database
version 50.31 To detect the domain in putative unpredicted proteins we ran
Exonerate32 using that profile over the genome sequence. The results were
compared with similar searches using the profiles available at PFAM (which
rendered only already-annotated proteins) and Prosite databases, as well as with
regular expression searches with motifs described in the literature (Table 1).
Cell culture and treatments. HeLa cells from American Type Culture
Collection and 293T were cultured in pyruvate-free high glucose Dulbecco’s
Modified Eagle’s Medium (DMEM; Gibco Life Technologies, Waltham, MA, USA)
supplemented with 10% fetal bovine serum (FBS; Invitrogen, Carlsbad, CA, USA),
200 mg/ml of penicillin, 100mg/ml of streptomycin and glutamine 2 mM (hereafter
referred to as PSQ). Cells were maintained at 37 1C and in a 5% CO2 atmosphere.
Cell maintenance is based on three splits per week using trypsin EDTA-Solution
0.05% (Invitrogen). HeLa cells were plated at a concentration of 150 000/ml in 6-
or 12-well plates and treated 24 h later, when they reached the concentration of
500 000/ml. 293T cells were plated at a concentration of 1 106/ml in 10 cm
plates for transfections.
Before glucose-deprivation or FBS-deprivation treatments, cells were washed
twice with FBS-free, pyruvate-free DMEM medium without glucose (Gibco Life
Technologies) or high-glucose, FBS-free DMEM, respectively. Glucose-deprivation
treatment is performed in PSQ-containing, glucose-free DMEM medium without
glucose supplemented with 10% dialyzed FBS. FBS-deprivation treatment was
performed in PSQ-containing high-glucose DMEM. For induction of cell death by
starvation in Earle’s Balanced Salt Solution (EBSS, Gibco Life Technologies), cells
were washed twice with EBSS before treating with EBSS supplemented with Hepes
25 mM.
ABT-737 (Selleck Chemicals, Houston, TX, USA) is used at 30 mM, chloroquine,
thapsigargin and actinomycin D (Sigma-Aldrich, St. Louis, MO, USA) at 100mM,
100mg/ml and 50 nM, respectively, interferon-gamma (Novus Bionova, Madrid,
Spain) at 100 ng/ml. TNF-a (Peprotech, Le-Perray-en-Yvelines, France, 10 ng/ml) is
added in combination with 10mM cycloheximide (Sigma-Aldrich) to induce cell
death.
For autophagy induction, cells were incubated in home-made EBSS (potassium
chloride 400 mg/ml, sodium bicarbonate 2.2 g/ml, sodium chloride 6.8 g/ml,
NaH2PO4-H2O 140 mg/ml, D-Glucose 1 g/ml) supplemented with 25 mM Hepes.
EBSS-Hepes treatment is performed after washing the cells twice with EBSS.
Autophagy flux was blocked by adding the protease inhibitors pepstatin A and
E64d (Sigma, St. Louis, MO, USA, 10 mM each) simultaneously with the treatments.
Cell viability. For analysis of viability, cells were harvested by combining
floating cells in the medium and adherent cells detached by trypsinization, and
subjected to FACS analysis to detect incorporation of propidium iodide 1mg/ml
Figure 5 ApoL2 does not regulate cell proliferation or sensitivity to ABT-737.
(a) HeLa cells were transfected with control siRNA or siRNA targeting ApoL2 and
then they were treated with the BH3 mimetic ABT-737 at 30 mM for 24 h. Cell death
was measured by PI incorporation and flow cytometry. Panel shows average and
S.E.M. of five independent experiments. (b) HeLa cells were transfected with control
1 siRNA or siRNAs against ApoL2 and growth analysis was performed at indicated
time points by crystal violet coloration. The lower panel shows western blot analysis
of ApoL2 silencing over time
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(10 min incubation in PBS) using Gallios Flow Cytometer Beckman Coulter.
Data were analyzed using FlowJo software, version 7.6.4.
Cell viability and number was additionally measured by crystal violet coloration. After
the indicated treatments, cells were covered with staining solution (0.2% crystal violet,
2% EtOH solution) and incubated for 20 min at room temperature. Cells were rinsed
twice with PBS and once with water and let dry for 16 h. Crystal violet-stained cells
were then resuspended in 10% SDS and absorbance was read at 595 nm in a BioTek
(Winooski, VT, USA) PowerWave XS microplate spectrophotometer.
Western blotting. Cell pellets were resuspended in RIPA buffer (Thermo
Scientific, Waltham, MA, USA) or lysis buffer (0.06 M Tris, 2% SDS) containing
protease inhibition cocktail (Roche, Basel, Switzerland) and phosphatase inhibitors
(PhosSTOP, Roche) and they were then sonicated.
For trichloroacetic acid (TCA) precipitation, the acid (Merck, Darmstadt,
Germany) was added to the sample at a final concentration of 13%, mixed
thoroughly and incubated overnight at 4 1C under rotation. The mixture was
centrifugated (16 000 g, 15 min, 4 1C), and the supernatant was discarded. The
pellet was resuspended in RIPA buffer.
Protein quantification was performed using Pierce BCA protein assay kit,
following the manufacturer’s instructions. 40mg of protein were diluted in 10ml of
laemmli buffer 4 (63 mM Tris-HCl, 10% glycerol, 2% SDS, 0.01% bromophenol
blue and 5% 2-mercaptoethanol), and PBS was added until 40 ml of total volume.
Lysates were boiled for 10 min at 96 1C and loaded in a 12% acrylamide gel. Mini-
protean (Bio-Rad, Hercules, CA, USA) electrophoresis tank was used to perform the
electrophoresis assay. Proteins were transferred to polyvinylidene fluoride (PVDF,
Millipore, Darmstadt, Germany) or nitrocellulose membranes (Bio-Rad) through
semi-dry transfer (1 h at 0.2 A/membrane). Transfer validation and loading charge
control was checked by ponceau dye (Sigma). PVDF membranes were blocked with
5% nonfat dry milk in Tween Tris-buffered saline (TTBS) and processed for
immunoluminiscence. Nitrocellulose membranes were blocked with Odyssey
Blocking Buffer (LI-COR Biosciences, Lincoln, NE, USA) and processed for
immunofluorescence using Odyssey Fc Imaging system. Primary and secondary
antibodies were incubated for 1 h at room temperature or overnight at 41C, in 5%
milk TTBS. Three 10-min TTBS washes in the shaker were performed before
developing by enhanced chemiluminescence (ECL; Pierce, Waltham, MA, USA) or
scanning the membrane using Odyssey Imaging System. Quantification of band
intensity was performed with Fiji/Image J software 1.47b.
Primary antibodies used for western blotting were: anti-actin (ICN clone 4),
polyclonal anti-ApoL2 (Sigma, HPA001078), anti-tubulin (Sigma, Clone TUB 2.1).
polyclonal antibody against p62 (Progen, Heidelberg, Germany), polyclonal
anti-LC3 (Abcam, Cambridge, UK), anti-HA (Sigma, clone HA-7), anti-Bcl-xL (Cell
Signaling, Beverly, MA, USA, 54H6), anti-Bcl-2 (Santa Cruz, Dallas, TX, USA, 100),
polyclonal anti-Mcl-1 (Santa Cruz, sc-819), polyclonal anti-Atg5 (CosmoBio, Tokyo,
Japan), anti-beclin-1 (BD Biosciences, Franklin Lakes, NJ, USA, 20/Beclin). HRP
secondary antibodies were: antimouse and anti-rabbit (Zymax, Bideford, UK) or
anti-guinea pig (Abcam). IRDye secondary anti-bodies against mouse or rabbit
(IRDye 800CW donkey anti-rabbit IgG1 1/15.000 or IRDye 680LT anti-mouse IgG
1/20 000) were from LI-COR Biosciences.
Plasmids and transient transfection. ApoL2 cDNA (NM_030882.2) was
purchased from Origene and subcloned into ampicillin resistant pcDNA3.1 plasmid
using EcoR1 and BamH1 restriction enzymes. Invitrogen PureLink kit was used to
extract the plasmid from competent bacteria (Promega, Fitchburg, WI, USA).
For death experiments, HeLa cells were transfected in six-well plates, using 4 ml
of Genejuice (Novagen, Darmstadt, Germany) and 2mg of total DNA. To normalize
until 2 mg, we completed with the empty plasmid pcDNA 3.1. pcDNA 3.1-Bcl-2
plasmid was generously provided by Dr. Jean-Ehrland Ricci (Nice, France). HA-
Noxa and pcDNA 3.1-Bmf were provided by Professor Seamus Martin (Dublin,
Ireland). pcDNA 3.1-HA-Bcl-2 and pcDNA 3.1-HA-Bcl-xL plasmids from Dr. Douglas
Green’s laboratory (Memphis, TN, USA) were used in the immunoprecipitation
assay. Cell death was analyzed by counting GFP positive dead cells against total
GFP positive cells using an Olympus IX70 inverted microscope. For immunopre-
cipitation, HeLa cells were transfected in 10 cm dishes, using 3mg of
polyethylenimine linear (PEI; Polyscience Europe, Heidelberg, Germany) per mg
of DNA. Cotransfection was performed using 10 mg of ApoL2 and 10mg of HA-Bcl-
xL or HA-Bcl-2 plasmid.
siRNA transfection. Cells were transfected at a density of 300 000/ml using
1.5ml of DharmaFECT 1 (Dharmacon, Lafayette, CO, USA) per milliliter of total
volume and following manufacturer’s instructions. siRNA concentration was
100 nM. After 24 h, medium was replaced with growth medium. Control sequences
were: 50-GUAAGACACGACUUAUCGC[dT][dT] (‘control 1’) and an ON-TARGET
plus siRNA pool of 4 oligos against mouse RIPK (Dharmacon; ‘control 2’). Three
different siRNA sequences were used against ApoL2: ApoL2-I (GCGGCAC
CAAUGUAGCAAA[dT][dT]), ApoL2-II (CAGUGUGGUAGAACUAGUA[dT][dT])
and ApoL2-III (CAAUGUUCUUACCUUAGUU[dT][dT]).
Immunofluorescence. Cells were cultured on glass coverslips pretreated
with poly-L-Lysine (Sigma). After 24 h they were incubated for 15 min in culture
medium at 37 1C and 5% CO2 with MitoTracker red 200 nM (Invitrogen) before
Figure 6 ApoL2 does not regulate autophagy. HeLa cells were transfected with siRNA Control 1 (labeled as siC) or siRNA against ApoL2-II (labeled as siApo) for 48 h and
then the medium was changed or they were incubated with EBSS for 6 h to induce autophagy. The protease inhibitors pepstatin and E64D (10 mM each) were used to block
autophagic flux. A representative western blot is shown in a. ApoL2 levels were quantified and are shown in b: data were weighted to ponceau or actin and then normalized
against Control 1-transfected untreated cells. (c) Quantification of relative LC3-II levels: data were weighted to ponceau or actin and then normalized against Control
1-transfected HeLa cells with protease inhibitors as control of basal autophagy. (d) Quantification of relative p62 levels: data were weighted to ponceau or actin and then
normalized against Control 1-transfected untreated cells. Graphs show average and S.D. of three independent experiments
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fixing, or they were directly fixed with a fresh 4% solution of paraformaldehyde for
20 min. Cells were then incubated with blocking buffer: 0.05% Triton, 3% BSA in PBS
for 1 h and kept overnight at 4 1C with primary antibodies diluted 1 : 200 in blocking
buffer: Ab rabbit anti-ApoL2 (Sigma), mouse anti-Lamp-2 (BD pharmigen, Franklin
Lakes, NJ, USA, CD107b, 555803), mouse anti-Calnexin (Santa Cruz, E-10,
sc-46669), goat anti-GRP94 (Santa Cruz, C-19, sc-1794). Cells were incubated with
secondary antibodies Alexa Fluor 568 red and 488 green (Life Technologies,
Carlsbad, CA, USA) diluted 1 : 400 in blocking buffer for 1 h. Then they were mounted
in Vectashield solution (Vector laboratories, Burlingame, CA, USA) on microscope
slides and visualized on a Leica TCS SP5 Spectral Confocal microscope with a HCX
PL APO lambda blue  63 1.4 oil objective lens. Acquisition software was LEICA
(Wetzlar, Germany) Application Suite Advanced Fluorescence (LAS AF) version
2.6.0.7266 and pictures were analyzed with Fiji/Image J software.
Immunoprecipitation. A total of 30ml of Protein G Magnetic Beads (Millipore)
were washed 3 in immunoprecipitation buffer and then incubated in 1 ml of
immunoprecipitation buffer with 1mg of antibody for 4 h at 4 1C under rotation.
10 106 cells were lysed in 500ml of immunoprecipitation buffer (20 mM Tris-HCl
(pH7.5), 137 mM NaCl, 1% Triton X-100, 2 mM EDTA (pH 8)) containing complete
protease inhibitor cocktail and incubated for 30 min in ice. A total of 1400mg of cell
extract were incubated overnight in 1 ml of immunoprecipitation buffer with the
antibody-coupled beads. The next day, beads were washed five times with
immunoprecipitation buffer and eluted with 60ml of immunoprecipitation buffer
containing 2% SDS. Then 20ml of laemmli buffer 4 were added, and samples
were boiled for 10 min at 95 1C. Eluted proteins were split in two gels of
SDS-polyacrylamide gel electrophoresis. Ten percent of the total protein subjected to
immunoprecipitation was loaded as input and 30ml of the remaining supernatant after
immunoprecipitation was also loaded to confirm immunodepletion. A total of 1mg of
anti-HA and anti-ApoL2 described above were used for immunoprecipitation.
Statistics. Error bars in the figures represent the standard error of the mean
(S.E.M.). Data were statistically analyzed to find significant differences using two-
tailed, paired Student’s t-test. Significant differences are marked in the figures with
* (Pr0.05) or ** (Pr0.0005).
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